AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates

What happened

AbbVie reported Q3 2026 revenue of $17.4 billion, up 10.3% from a year earlier and roughly in line with analysts' $17.34 billion estimate. Adjusted profit was $3.82 per share, 1.3% above consensus, and the company raised and narrowed its full-year adjusted profit guidance to a $13.97 midpoint.

Confirmed

Global impact / market context

Higher revenue and a 36% operating margin, up from 12.1% a year earlier, mean AbbVie keeps more profit from each sale, which supports cash available for dividends, drug launches and acquisitions. The raised guidance signals management expects that momentum to continue rather than fade.

Analyst inference

Revenue merely matching estimates while profit beat slightly suggests expectations were already high for this $513.9 billion company. Because AbbVie also raised its dividend, income-focused investors may weigh the stronger payout against whether sales growth can keep pace with those elevated expectations.

Analyst inference

What to watch

1. Watch whether full-year adjusted profit lands near the $13.97 midpoint management now guides to, since missing that raised target could reverse the confidence shown by the dividend increase. Confirmed
2. Track sales from newly approved drugs and the completed Apogee Therapeutics acquisition, because management presented these as the basis for stronger long-term growth and higher guidance. Proposed
3. Monitor whether the 36% operating margin holds, since holding more profit per sale is what funds the dividend and acquisitions; a fall back toward last year's 12.1% would pressure cash available. Analyst inference

Evidence

• stockstory.org